Literature DB >> 1448186

Reduction of postischemic leukocyte-endothelium interaction by adenosine via A2 receptor.

D Nolte1, A Lorenzen, H A Lehr, F J Zimmer, K N Klotz, K Messmer.   

Abstract

The adhesion of leukocytes to the endothelium of postcapillary venules hallmarks a key event in ischemia-reperfusion injury. Adenosine has been shown to protect from postischemic reperfusion injury, presumably through inhibition of postischemic leukocyte-endothelial interaction. This study was performed to investigate in vivo by which receptors the effect of adenosine on postischemic leukocyte-endothelium interaction is mediated. The hamster dorsal skinfold model and fluorescence microscopy were used for intravital investigation of red cell velocity, vessel diameter, and leukocyte-endothelium interaction in postcapillary venules of a thin striated skin muscle. Leukocytes were stained in vivo with acridine orange (0.5 mg kg-1 min-1 i.v.). Parameters were assessed prior to induction of 4 h ischemia to the muscle tissue and 0.5 h, 2 h, and 24 h after reperfusion. Adenosine, the adenosine A1-selective agonist 2-chloro-N6-cyclopentyladenosine (CCPA), the A2-selective agonist CGS 21,680, the non-selective adenosine receptor antagonist xanthine amine congener (XAC), and the adenosine uptake blocker S-(p-nitrobenzyl)-6-thioinosine (NBTI) were infused via jugular vein starting 15 min prior to release of ischemia until 0.5 h after reperfusion. Adenosine and CGS 21,680 significantly reduced postischemic leukocyte-endothelium interaction 0.5 h after reperfusion (p less than 0.01), while no inhibitory effect was observed with CCPA. Coadministration of XAC blocked the inhibitory effects of adenosine. Infusion of NBTI alone effectively decreased postischemic leukocyte-endothelium interaction. These findings indicate that adenosine reduces post-ischemic leukocyte-endothelium interaction via A2 receptor and suggest a protective role of endogenous adenosine during ischemia-reperfusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1448186     DOI: 10.1007/bf00165307

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  26 in total

1.  Quantitative analysis of microcirculatory disorders after prolonged ischemia in skeletal muscle. Therapeutic effects of prophylactic isovolemic hemodilution.

Authors:  M D Menger; F U Sack; J H Barker; G Feifel; K Messmer
Journal:  Res Exp Med (Berl)       Date:  1988

Review 2.  Signal transduction and cytoskeletal activation in the neutrophil.

Authors:  G M Omann; R A Allen; G M Bokoch; R G Painter; A E Traynor; L A Sklar
Journal:  Physiol Rev       Date:  1987-01       Impact factor: 37.312

Review 3.  The role of adenosine in the regulation of coronary blood flow.

Authors:  R M Berne
Journal:  Circ Res       Date:  1980-12       Impact factor: 17.367

4.  Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins.

Authors:  M B Lawrence; T A Springer
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

5.  Reduction of postischemic reperfusion injury by the vasoactive drug buflomedil.

Authors:  D Nolte; H A Lehr; F U Sack; K Messmer
Journal:  Blood Vessels       Date:  1991

6.  Cyclic adenosine monophosphate and diacylglycerol. Mutually inhibitory second messengers in cultured rat inner medullary collecting duct cells.

Authors:  I Teitelbaum
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

7.  Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation.

Authors:  M B Grisham; L A Hernandez; D N Granger
Journal:  Am J Physiol       Date:  1989-11

8.  A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo.

Authors:  K E Arfors; C Lundberg; L Lindbom; K Lundberg; P G Beatty; J M Harlan
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

9.  Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells.

Authors:  B N Cronstein; R I Levin; J Belanoff; G Weissmann; R Hirschhorn
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

10.  2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors.

Authors:  M J Lohse; K N Klotz; U Schwabe; G Cristalli; S Vittori; M Grifantini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

View more
  4 in total

Review 1.  A(2A) adenosine receptors in human peripheral blood cells.

Authors:  S Gessi; K Varani; S Merighi; E Ongini; P A Borea
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes.

Authors:  B B Fredholm; Y Zhang; I van der Ploeg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

3.  Spinal cord adenosine receptor stimulation in rats inhibits peripheral neutrophil accumulation. The role of N-methyl-D-aspartate receptors.

Authors:  G W Bong; S Rosengren; G S Firestein
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

4.  Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation.

Authors:  Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  Respir Res       Date:  2009-06-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.